Evidence map›Paper›PMID 32944962›Full record

ArticleThe Journal of pathology2021

Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.

Assunta De Rienzo, Lucian R Chirieac, Yin P Hung, David T Severson, Samuel Freyaldenhoven, Corinne E Gustafson, Nhien T Dao, Claire V Meyerovitz, Michela E Oster, Roderick V Jensen and 3 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
3.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Recurrent Tumor Suppressor Alterations in Primary Pericardial Mesothelioma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  14. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
    Review
  15. Molecular Characterization of Peritoneal Mesotheliomas.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2022
    Article
  16. Review
  17. Molecular characterization of pleomorphic mesothelioma: a multi-institutional study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Article
  18. Pleural mesothelioma classification-update and challenges.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Assunta De RienzoThe Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4397-9805
Lucian R Chirieac *Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4383-6938
Yin P Hung *Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8568-1591
David T SeversonThe Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Samuel FreyaldenhovenThe Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Corinne E GustafsonThe Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Nhien T DaoThe Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Claire V MeyerovitzThe Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Michela E OsterThe Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Roderick V JensenDepartment of Biological Sciences, Virginia Tech, Blacksburg, VA, USA.ORCID 0000-0002-3055-4296
Beow Y YeapDepartment of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Raphael BuenoThe Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1258-8468
William G RichardsThe Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program (www.impmeso.org), Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0990-8317
Brigham and Women's Hospital · USHarvard University · USVirginia Tech · US

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6M
Validation of Prognostic and Diagnostic Molecular Tests in MesotheliomaR01CA120528 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUENO, RAPHAEL · 2006 to 2021
$4.8M
NCI NIH HHS NCI 2 R01 CA120528-11A1NCI NIH HHS P30 CA006516NCI NIH HHS R01 CA120528
6 · The paper itself

Abstract

BRCA1-associated protein-1 (BAP1) expression is commonly lost in several tumors including malignant pleural mesothelioma (MPM). Presence or absence of immunohistochemical BAP1 nuclear staining in tumor cells is currently used for differential diagnosis of MPM. In this study, a large cohort of 596 MPM tumors with available clinical data was analyzed to examine associations of BAP1 staining pattern with clinical and molecular features that may reflect the impact of BAP1 mutation on MPM biology. Cases were classified according to the BAP1 staining pattern of tumor cells. Exome and RNA-sequencing data were available for subsets of cases. Levels of mRNA encoding claudin 15 (CLDN15) and vimentin (VIM) were determined using RT-qPCR on 483 cases to estimate the relative proportions of epithelial-like and mesenchymal-like components in each tumor. Four BAP1 staining patterns were observed: single-pattern nuclear staining (36%), single-pattern cytoplasmic staining (25%), single-pattern absent staining (12%), and combinations of these staining patterns (27%). This study confirmed prior reports that nuclear BAP1 is more frequently associated with wild-type BAP1 and sarcomatoid histology. However, no associations between BAP1 staining pattern(s) and mutations in specific protein domains and/or mutation type were observed. BAP1 staining patterns were significantly associated (p < 0.001) with BAP1 gene expression, MPM histologic subtypes, molecular clusters, and markers of epithelial-to-mesenchymal transition. Frequent observation of combinations of BAP1 staining patterns in MPM tumors indicated intra-tumoral heterogeneity of BAP1 status. Cytoplasmic BAP1 staining was identified as a putative indicator of favorable prognosis in non-epithelioid MPM. In conclusion, novel significant associations among different BAP1 staining patterns and subgroups of MPM tumors were observed, suggesting that the role of BAP1 in tumor progression may be more complex than its presumed tumor suppressor function. Cytoplasmic staining was identified as a putative indicator of favorable prognosis in non-epithelioid MPM, potentially addressing a critical need in clinical decision-making in this disease. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorCell NucleusDNA Mutational AnalysisEpithelial-Mesenchymal TransitionFemaleHumansImmunohistochemistryMaleMesothelioma, MalignantMiddle AgedMutationPleural NeoplasmsBAP1 protein, humanBiomarkers, TumorTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1epithelial-to-mesenchymal transitiongene expressionimmunohistochemistryintra-tumor heterogeneitymesotheliomaprognostic biomarkertumor suppressor gene

Identifiers

PMID32944962
PMCPMC7756745
OpenAlexW3087637892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.